Status:

ENROLLING_BY_INVITATION

Feasibility of Improving Glycemia With Heat Therapy to Prevent AD

Lead Sponsor:

University of Kansas Medical Center

Collaborating Sponsors:

National Institute on Aging (NIA)

Conditions:

Healthy Aging

Alzheimer Disease

Eligibility:

All Genders

65+ years

Phase:

NA

Brief Summary

The investigators will determine if heat therapy can improve blood (Aim 1) and brain (Aim 2) glucose metabolism in cognitively healthy older adults (65+) who are at risk for AD. The investigators will...

Detailed Description

Aim 1. Examine the effects of heat therapy on blood glucose regulation in older adults at risk for AD. The Investigators will determine the ability of 10 weeks of heat therapy (3 days/week) to improve...

Eligibility Criteria

Inclusion

  • Age 65 and older
  • Stable medication doses (\>1 month)
  • Post-menopausal
  • Clinical Dementia Rating (CDR) of 0
  • History of or current metabolic impairment (i.e. metabolic syndrome, pre-diabetes, Type 2 Diabetes, etc)

Exclusion

  • Excluded from or unable to complete an MRI scan. MRI compatible pacemakers will require cardiologist clearance prior to enrolling.
  • ACSM Risk score stratification of "High" unless cleared by a physician prior to participation.
  • Myocardial infarction or symptoms of coronary artery disease in the last 2 years.
  • History of or current diagnosis of disorders with the potential to impair cognition (i.e. AD, Parkinson's disease, stroke (defined as clinical episode w/ neuroimaging evidence in appropriate area to explain symptoms)).
  • Insulin-dependent (Type 1) Diabetes Mellitus.
  • Clinically significant chronic disease such as cancer, HIV, or acquired immunodeficiency syndrome.
  • Clinically significant depressive symptoms that may impair cognition, use of psychoactive and investigational medications, and significant visual or auditory impairment.
  • Orthopedic complications that would preclude individuals from safely entering a hot tub.
  • Untreated hypothyroidism or diseases associated with heat intolerance (i.e. Graves disease, etc).
  • Contraindication for temperature pill ingestion (i.e. inflammatory bowel disease, diverticulitis or related).

Key Trial Info

Start Date :

February 27 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2027

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06023407

Start Date

February 27 2024

End Date

January 1 2027

Last Update

March 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Univeristy of Kansas Medical Center

Kansas City, Kansas, United States, 66160